Vera Health raises $28.5m Series A as free clinical AI search reaches 800,000 clinicians

Vera Health, a San Francisco clinical AI search company, said on 27 October 2026 that it had raised a $28.5 million Series A led by Threshold Ventures, with Mantis VC and SV Angel joining and existing backers Y Combinator and Gradient adding to their stakes¹. The round takes the company's total funding to $32 million¹.

The round and the usage behind it

The headline for investors is the gap between capital and reach. Vera Health says more than 800,000 clinicians across 190 countries use its tool, built by a team of 12 people, and that most users found it through a colleague rather than through a sales channel¹. A year earlier, the company says, only a few thousand clinicians were on the platform¹.

The download figures are equally aggressive. Vera Health says it has been the most downloaded clinical app worldwide on the App Store and Google Play in every month since June, citing Appark data, and that in September it was downloaded more often than OpenEvidence and Doximity combined¹. Monthly downloads had more than tripled since February, and daily questions have grown from a few thousand to hundreds of thousands¹. The release also says that a few months after the raise, the company already had more daily active users than it had monthly active users when the round was struck¹.

Europe is where adoption is densest. On company data, about 1 in 4 physicians in Spain and Italy use the platform, and 1 in 7 in France¹. Co-founder Maxime Allouch said most tools in the category "were built for a single geography", and the product weights locally relevant guidelines over international literature¹.

The product searches more than 60 million peer-reviewed papers, guidelines, consensus statements and drug labels, grades each source by study design, cohort size, recency and journal quality, and colour-codes every claim by strength of evidence¹. A feature called Vera Spaces lets health systems load their own protocols and pathways alongside national guidance¹. The American College of Emergency Physicians has a partnership that brings its clinical policies into the tool with attribution¹.

What it means for the market

Clinical evidence search is becoming a crowded, venture-funded category, and Vera Health is positioning itself directly against OpenEvidence and Doximity on distribution¹. Its pitch to buyers is evidence grading rather than fluent answers: the company argues that general-purpose chatbots tend to present uncertain findings as if they were settled¹.

For health systems in Europe, the more relevant point is that the tool is already in heavy use by their physicians without any institutional purchase, because it is free to licensed clinicians and trainees and will stay so¹. That puts CMIOs and clinical governance teams in the position of reacting to adoption that has already happened. Vera Spaces is the obvious route to an enterprise relationship, and the company says the new money will fund deeper partnerships with health systems, medical societies and publishers, expansion into more markets and further work on its evidence infrastructure¹. The release does not say how, or whether, the company plans to charge institutions.

The company says it does not train on clinicians' questions and is HIPAA and GDPR compliant and SOC 2 Type II certified¹. The release does not mention medical device regulation.

Caveats

Every usage and penetration figure here comes from the company's own announcement, including the share of physicians in Spain, Italy and France, and none has been independently verified¹. The clinical benefit is still being tested. Bernard Chang, the company's chief scientific advisor at Columbia University, said whether the tool reliably improves clinical reasoning is what the company is "now evaluating rigorously" inside academic medical centres¹.